Sugi Predict

Sugi Predict / Compounds / SCHEMBL24853447

SCHEMBL24853447

SCHEMBL24853447

C#CC1(NCc2ccc(OC)cc2)CCN(Cc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 6/20 0.53
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.48
▸ MMP1 P03956 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ ADAM17 P78536 1/20 0.46
▸ NR3C1 P04150 1/20 0.46
▸ CYP2D6 P10635 3/20 0.45
▸ TSHR P16473 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ GHSR Q92847 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30318699 0.78 SIGMAR1 (0.42) SIGMAR1MEN1KMT2AKDM4EMMP1
SCHEMBL24853455 0.78 SIGMAR1 (0.42) SIGMAR1MEN1KMT2AKDM4EMMP1
SCHEMBL7016275 0.76 SIGMAR1 (0.72) SIGMAR1MEN1KMT2ACYP2D6TSHR
SCHEMBL4125351 0.73 SIGMAR1 (0.56) SIGMAR1MEN1KMT2AKDM4EMMP1
SCHEMBL31099142 0.72 LMNA (0.49) MEN1KMT2AKDM4EMMP1MMP9
SCHEMBL2913689 0.72 SIGMAR1 (0.49) SIGMAR1MEN1KMT2ANR3C1CYP2D6
SCHEMBL28217942 0.72 SIGMAR1 (1.00) SIGMAR1MEN1KMT2AKDM4EALDH1A1
SCHEMBL9232122 0.72 OPRM1 (0.58) SIGMAR1MEN1KMT2ACYP2D6TSHR
SCHEMBL8896675 0.71 SMN1; SMN2 (0.59) SIGMAR1MEN1KMT2AMMP1MMP9
SCHEMBL24853451 0.71 MEN1 (0.42) SIGMAR1MEN1KMT2AKDM4EMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116113635-B Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2025-03-18 — — CN disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 — — US disclosed
WO-2024255412-A1 SPIRO HETEROCYCLIC COMPOUND AND USE THEREOF 广州必贝特医药股份有限公司 2024-12-19 — — WO disclosed
EP-4161927-B9 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-11-06 — — EP disclosed
CN-118510780-A Spiro heterocyclic compounds and uses thereof 广州必贝特医药股份有限公司 2024-08-16 — — CN disclosed
EP-4161927-B1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-08-07 — — EP disclosed
CN-117586259-A Spirocyclic MC4R antagonist compound, pharmaceutical composition and application thereof in medicine 长春金赛药业有限责任公司 2024-02-23 — — CN disclosed
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 — — US disclosed
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 — — US disclosed
CN-116113635-A Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2023-05-12 — — CN disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 — — US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 — — US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 — — US disclosed
EP-4161927-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2023-04-12 — — EP disclosed
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-01-19 — — US disclosed
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-01-19 — — US disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 — — WO disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 — — WO disclosed
WO-2021250541-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 SIGMAR1 502/4885MEN1 1380/4885KMT2A 1048/4885
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC5R SIGMAR1 640/4885MEN1 182/4885KMT2A 1777/4885
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR MC4R, MC2R, NPY4R SIGMAR1 590/4885MEN1 527/4885KMT2A 2106/4885
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof MC4R, MC3R, MC5R SIGMAR1 640/4885MEN1 182/4885KMT2A 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.